Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation, Pelvic definitive concurrent chemoradiation.
- Who it may be relevant to
- Registry conditions: Cervical Cancer. Basic parameters: 18 years — 75 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer: a Prospective, Randomized, Multicenter Study
Overview
Para-aortic lymph node metastasis is a poor prognostic factor for locally advanced cervical cancer, but false negative diagnosis is easy to occur. The aim of this trial was to investigate whether para-aortic prophylactic radiotherapy improves disease-free survival in patients with positive pelvic lymph nodes below the common iliac artery.
Detailed description
This clinical trial enrolled participants with locally advanced cervical cancer with positive pelvic lymph nodes below the common iliac region diagnosed by Positron emission tomography-computed tomography(PET-CT). Participants should be able to receive concurrent cisplatin chemotherapy. No anti-tumor treatment was given before randomization. Participants will be randomly assigned to two groups. The study group will receive radiotherapy of pelvic and para-aorta, concurrent chemotherapy and brachytherapy, and the control group will receive pelvic radiotherapy, concurrent chemotherapy and brachytherapy.
Interventions
- Radiation Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation
The para-aortic area, from left renal vein level to abdominal aorta bifurcation level，will be prophylactic irradiation. The other intervention is the same as control arm. - Radiation Pelvic definitive concurrent chemoradiation
Pelvic definitive concurrent chemoradiation, including external beam radiotherapy, concurrent chemotherapy and brachytherapy.
Primary outcome measures
- Progression-free survival rate [Time frame: 3-year]
Secondary outcome measures (6)
- Overall survival rate [Time frame: 3-year]
- Para-aortic recurrence rate [Time frame: 3-year]
- Distant recurrence rate [Time frame: 3-years]
- Side effects [Time frame: 3-year]
- Quality of life (QOL) assessed by EORTC QLQ-C30 v3 [Time frame: 1-month and 6-month]
- Quality of life (QOL) assessed by EORTC QLQ-CX24 [Time frame: 1-month and 6-month]
Eligibility criteria
Inclusion criteria
- The patients voluntarily participated in the study and signed the informed consent
- 18-75 female
- Cervical squamous cell carcinoma / adenocarcinoma / adenosquamous cell carcinoma
- According to International Federation of Gynecology and Obstetrics(FIGO) 2009 stage, stage ⅠB2 - ⅣA with positive pelvic lymph nodes and negative common iliac and paraaortic lymph nodes diagnosed by PET-CT
- Cisplatin chemotherapy is acceptable
- Eastern Cooperative Oncology Group(ECOG) score 0-1
- The expected survival was more than 6 months
- Women of childbearing age must have a pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and they are willing to use appropriate contraceptive methods during the test
- According to the judgment of the researcher, those who can comply with the trial protocol
Exclusion criteria
- Uncontrolled severe infection
- Combined with other malignant tumor patients who need treatment and / or new diagnosis within 5 years
- The patient has received anti-tumor treatment
- Liver cirrhosis, decompensated liver disease, chronic renal insufficiency and renal failure
- History of immunodeficiency, including HIV positive or other acquired congenital immunodeficiency disease
- Myocardial infarction, severe arrhythmia and grade 2 or more congestive heart failure (NYHA classification)
- Patients with previous pelvic artery embolization
- Previous radiotherapy for pelvic malignant tumor
- There was a history of severe allergic reaction to platinum containing chemotherapy drugs
- Complications, need to be taken during the treatment of liver and kidney function damage drugs, such as tuberculosis
- The patients who could not understand the content of the experiment and could not cooperate and refused to sign the informed consent
- Patients with accompanying diseases or other special circumstances that seriously endanger the safety of patients or affect the completion of the study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 7 centers
- Zhejiang Cancer Hospital — Hangzhou
- The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou
- Jinhua Municipal Central Hospital Medical Group — Jinhua
- Lishui People's Hospital — Lishui
- Ningbo First Hospital — Ningbo
- Taizhou Central Hospiatl — Taizhou
- Chongqing University Three Gorges Hospital — Wanzhou
Identifiers
NCT: NCT04974346 · CARTOnG 2101